Floatz logo

Xaliplatin

Colon Carcinoma

Sun Yat-sen UniversitySmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
65/ 100

Competitive context

153 Active assets in the Colon Carcinoma cohort.

Asset / SponsorPhaseRating
Floxuridine
City of Hope Medical Center
Phase 2BBB
Fluorouracilum
Akeso
Phase 4BB
Pertuzumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB
Palbociclib
Lebanese University
Phase 2BB
Trastuzumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Xaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →